# Aktis Oncology, Inc.: financial statements, quarterly

AKTS · Nasdaq · CIK 2035832 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/akts.md) · [Financials](/companies/akts/financials.md) · [Filings](/companies/akts/filings.md) · [Insiders](/companies/akts/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/akts/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.4](/filings/0001193125-26-216749.md) | [1.6](/filings/0001193125-26-349144.md) | [3.2](/filings/0001193125-26-216749.md) | [3.4](/filings/0001193125-26-349144.md) |
| Research and development | $m | [15.9](/filings/0001193125-26-216749.md) | [18.6](/filings/0001193125-26-349144.md) | [20.0](/filings/0001193125-26-216749.md) | [25.3](/filings/0001193125-26-349144.md) |
| Operating income | $m | [(18.1)](/filings/0001193125-26-216749.md) | [(21.0)](/filings/0001193125-26-349144.md) | [(22.7)](/filings/0001193125-26-216749.md) | [(28.9)](/filings/0001193125-26-349144.md) |
| Net income | $m | [(15.0)](/filings/0001193125-26-349144.md) | [(18.1)](/filings/0001193125-26-349144.md) | [(18.3)](/filings/0001193125-26-349144.md) | [(24.1)](/filings/0001193125-26-349144.md) |
| Diluted EPS | $ per share | [(18.60)](/filings/0001193125-26-216749.md) | [(22.39)](/filings/0001193125-26-349144.md) | [(0.38)](/filings/0001193125-26-216749.md) | [(0.44)](/filings/0001193125-26-349144.md) |
| Basic EPS | $ per share | [(18.60)](/filings/0001193125-26-216749.md) | [(22.39)](/filings/0001193125-26-349144.md) | [(0.38)](/filings/0001193125-26-216749.md) | [(0.44)](/filings/0001193125-26-349144.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [58.3](/filings/0001193125-26-216749.md) | [110](/filings/0001193125-26-349144.md) | [37.8](/filings/0001193125-26-349144.md) | [372](/filings/0001193125-26-216749.md) | [82.5](/filings/0001193125-26-349144.md) |
| Current assets | $m | not reported | not reported | not reported | [230](/filings/0001193125-26-349144.md) | [544](/filings/0001193125-26-216749.md) | [525](/filings/0001193125-26-349144.md) |
| Total assets | $m | not reported | not reported | not reported | [265](/filings/0001193125-26-349144.md) | [577](/filings/0001193125-26-216749.md) | [558](/filings/0001193125-26-349144.md) |
| Current liabilities | $m | not reported | not reported | not reported | [31.2](/filings/0001193125-26-349144.md) | [27.9](/filings/0001193125-26-216749.md) | [32.1](/filings/0001193125-26-349144.md) |
| Total liabilities | $m | not reported | not reported | not reported | [77.6](/filings/0001193125-26-349144.md) | [70.7](/filings/0001193125-26-216749.md) | [72.8](/filings/0001193125-26-349144.md) |
| Shareholders' equity | $m | [(87.8)](/filings/0001193125-26-349144.md) | [(102)](/filings/0001193125-26-349144.md) | [(118)](/filings/0001193125-26-349144.md) | [(146)](/filings/0001193125-26-349144.md) | [506](/filings/0001193125-26-349144.md) | [485](/filings/0001193125-26-349144.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(17.5)](/filings/0001193125-26-216749.md) | [(16.2) d](/filings/0001193125-26-349144.md) | [(24.2)](/filings/0001193125-26-216749.md) | [(20.6) d](/filings/0001193125-26-349144.md) |
| Capital expenditure | $m | [1.9](/filings/0001193125-26-216749.md) | [1.5 d](/filings/0001193125-26-349144.md) | [1.9](/filings/0001193125-26-216749.md) | [1.3 d](/filings/0001193125-26-349144.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.8](/filings/0001193125-26-216749.md) | [0.8](/filings/0001193125-26-349144.md) | [48.6](/filings/0001193125-26-216749.md) | [55.3](/filings/0001193125-26-349144.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.